Innovotech Inc. · TSXV:IOT
Innovotech — Investor Presentation (December 2020)
16 slides from Innovotech's investor presentation, December 2020
Slide 1: Corporate Presentation
Corporate Presentation TSX-V:IOT A PROFITABLE REVENUE PLATFORM A GROWING ASSET PLATFORM THE BASE ON WHICH WE BUILD A TAX PLATFORM Our plan is to use time, effort, discipline, and innovation to deliver a diversified Canadian Biotech
Slide 2: Brief History
Brief History 2003 Innovotech is listed on the TSX-V. Our business of contract research and manufacture and sale of the MBEC Assay® Kit continues today. 2014 - Time, effort, and money were spent on R&D at the expense of the base business. 2016 The anti-bacterial, InnovoSIL™-1, is the single success
Slide 3: Our Business – Contract Research
Our Business 1 – Contract Research We are a leader in contract research testing coated medical devices like implants for their susceptibility or resistance to formation of microbial biofilms that cause chronic infections and diseases in humans. • We have methodologies, equipment, and long experience
Slide 4: Our Business – MBEC Assay & InnovoSIL™-1
Our Business 2 – MBEC Assay & InnovoSIL™-1 MBEC ASSAY® KITS Innovotech makes & sells globally the MBEC Assay®, a high throughput biofilm growth device. Any hard surface disinfectant claiming effectiveness against biofilms must pass tests based on the Innovotech MBEC growth device. The Company develo
Slide 5: Innovotech is one of few profitable, listed Canadian micro-cap biotechs
Innovotech is one of few profitable, listed Canadian micro-cap biotechs Q2, Q3 2020 Revenues were 26% above 2019 comparable quarters and 64% above 2018 comparable quarters Q2 2020 posted a net profit of $121,974 Q3 2020 posted a net profit of $93,218 working capital of $642,046 compares with $148,03
Slide 6: Revenue & Income – 8 Quarters
Revenue & Income – 8 Quarters $400,000 NET INCOME REVENUE $350,000 $300,000 $250,000 $200,000 $150,000 $100,000 $50,000 $- $(50,000) $(100,000) $(150,000) Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 December 2020 www.innovotech.ca 6
Slide 7: Recent Corporate Developments
Recent Corporate Developments Tangible Progress We are using profits, our strong balance sheet & shares to invest in businesses or products targeting larger markets than our business: Q3 2020 investment acquisition • In skin care, Innovotech acquired the right to earn a 60% interest in Nou Life Scie
Slide 8: Internal Lean Growth Plan
Internal Lean Growth Plan Organic growth – 2021 - $40,000 budget • Penetrate the agricultural laboratory market with our plant-friendly cellulose-coated MBEC Assay® plate making it a preferred device for that market • Continue to work up devices and products to separate us from competition and impro
Slide 9: External Growth Plan - Investment
External Growth Plan - Investment Growth through investment Innovotech seeks right-sized investment opportunities such as the probiotics and skin cream acquisitions to extend our reach, diversify our assets and open avenues to larger markets. This works in parallel with the “Lean Growth” plan: • For
Slide 10: External Growth Plan - Acquisition
External Growth Plan - Acquisition Whole company acquisition The Bait Prior year’s NOLs and SRED tax credits, provide a tax pool of $7.5 million available to reduce our future net income for tax purposes. The pools can do the same for an acquired company. These pools do not start to expire until ~20
Slide 11: Revenue & Profit/Loss – 5 Year trend
Revenue & Profit/Loss – 5 Year trend $1,200,000 NET INCOME REVENUE $1,100,000 $1,000,000 $900,000 $800,000 $700,000 $600,000 $500,000 $400,000 $300,000 $200,000 $100,000 $- $(100,000) $(200,000) $(300,000) $(400,000) 2015 2016 2017 2018 2019 December 2020 www.innovotech.ca 11
Slide 12: Revenue & Profit/Loss – 8 Quarters
Revenue & Profit/Loss – 8 Quarters $400,000 NET INCOME REVENUE $350,000 $300,000 $250,000 $200,000 $150,000 $100,000 $50,000 $- $(50,000) $(100,000) $(150,000) Q4 2018 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 December 2020 www.innovotech.ca 12
Slide 13: Who we are
Who we are Officers & Management Directors Dr. James Timourian President Dr. James Timourian, PhD* Alan Savage CFO Alan Savage* Dr. Amin Omar COO Dr. Gerard Tertzakian, PhD Dr. Craig Milne CBDO David Tam, BSc. Pharma,LLB Dr. Tyler Boone Lab Mgr. Dr. Craig Milne, PhD, MBA* Dr. Patricia Nadworny QC Mg
Slide 14: Mission & Vision of Innovotech
Mission & Vision of Innovotech Scale up Innovotech to be a significant, innovative, profitable participant in the Canadian biotech sector. The time frame for the mission is not a short one. Innovotech has a knowledgeable, committed, invested and incentivized Board. It has a major shareholder and man
Slide 15: Company Information
Company Information Share capital: • Authorized Unlimited • Issued 38,274,612 – Never consolidated Directors hold as of AGM, 13 October 2020: • James Timourian 2,051,812 • Gerry Tertzakian 1,041,998 • Craig Milne 10,000 • Karen Farkas 15,000 • Bernard Grobbelaar 65,000 • David Tam 592,000 • Alan Sav
Slide 16: Disclaimer
Disclaimer This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking stat